GeneDx Holdings (WGS) Receivables (2020 - 2026)

GeneDx Holdings has disclosed Receivables across 7 years of filings, most recently posting $76.9 million for Q1 2026.

• In Q1 2026, Receivables rose 67.3% year-over-year to $76.9 million; the TTM figure through Mar 2026 stood at $76.9 million (up 67.3% YoY), while the FY2025 annual figure was $74.4 million, up 97.64% from the prior year.
• Receivables grew to $76.9 million in Q1 2026, from $74.4 million in the prior quarter.
• Over the last five years, Receivables for WGS reached as high as $76.9 million in Q1 2026 and fell as low as $445000.0 in Q4 2023.
• The 5-year median for Receivables is $38.2 million (2024), against an average of $38.0 million.
• Annual changes were most pronounced in 2023 — Receivables plunged 98.94% — and 2024, when it soared 8355.96%.
• A 5-year view of Receivables shows it stood at $2.2 million in 2022, then tumbled by 79.85% to $445000.0 in 2023, then soared by 8355.96% to $37.6 million in 2024, then jumped by 97.64% to $74.4 million in 2025, then rose by 3.44% to $76.9 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $76.9 million, $74.4 million, and $60.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.